Getting ready for #ASH26? Consider simultaneous publication with #JCO Journals. Send an inquiry before October 16 to [email protected] for consideration. 📅

Learn more at: https://bit.ly/4hji6tz

New in JCO Oncology Advances: Genomic profiling of 23,760 cases found TP53 alterations in 53%, including the targetable Y220C mutation in 1.1%, and distinct co-alteration patterns—insights for future p53-directed therapies.

Read more: https://bit.ly/4yK2wie
#BreastCancer #bcsm

A noninvasive spatiotemporal heterogeneity biomarker based on 18F-FDG PET-CT reliably predicted treatment response and prognosis in unresectable LA-NSCLC, offering insights to support personalized clinical decision making and precision oncology.

Read the article: https://bit.ly/4y5Nq5p

Does prior systemic chemotherapy exposure influence subsequent response to ROS1 tyrosine kinase inhibitors (TKIs) in ROS1-rearranged non-small-cell lung cancer? Learn more in this #JCOPO systematic review.

Read the article. https://bit.ly/4zc5BHH

#NSCLC

Getting ready for #SABCS26? Consider simultaneous publication with #JCO Journals. Send an inquiry before October 8 for consideration.📅

Learn more at: https://bit.ly/4hji6tz

Can early #ctDNA kinetics tell us more than PSA alone in #mCRPC?

This review examines ctDNA across ARPIs, chemotherapy, PARP inhibitors & PSMA-targeted radioligand therapy.

Read about the findings. https://bit.ly/4hepzeK
#ProstateCancer #LiquidBiopsy

🎧 Happy #InternationalPodcastDay!

Whether you're commuting, rounding, or taking a break, stay at the forefront of oncology with the JCO Journal Podcasts.

📲 Tune in on Apple Podcasts, Spotify, or your favorite platform: ascopubs.org/podcasts

Vemurafenib provides clinically meaningful disease control in BRAF-mutant pediatric and young adult glioma. Component-specific imaging may improve response assessment, while the observed early rebound supports close surveillance and careful planning when stopping therapy.

https://bit.ly/4yY8U55

JCO Associate Editor Prof. Brigette Ma joined JCO authors and oncology experts for a dedicated JCO session at #CSCO2026, sharing insights on high-impact research, responsible AI, peer review and global oncology publishing. Thank you to CSCO for a great exchange!

The MRF-based habitat framework noninvasively decodes ITH, improves preoperative IDH genotyping, and identifies pathophysiologically distinct subregions with prognostic relevance.

Read the article. https://bit.ly/4yhdHOU

#GI27 abstract submitted? ✅ Consider simultaneous publication with #JCO Journals. Send an inquiry before Nov. 17 for consideration.

Learn how at: https://bit.ly/4hji6tz

This #TAPUR Study provides new information on the efficacy of palbociclib in heavily pretreated patients with ovarian cancer with CDKN2A alterations, warranting further study.

Read the article. https://bit.ly/4rkBMSf
#gynonc

Listen to the latest @ascocancer.bsky.social #JCO Cancer Stories: The Art of Oncology episode "Purple Blossoms” by Dr. Ramesh Gopal who explores treating an aggressive disease in an underserved area.

https://bit.ly/4hcr4c5

#JCOPO Editor-in-Chief Emeritus Dr James Ford & @ascocancer.bsky.social TAPUR Study Founding PI Dr Richard Schilsky discuss the 10-year anniversary of the Targeted Agent and Profiling Utilization Registry (TAPUR)™ Study & its relationship w/ the journal. Listen to the podcast. https://bit.ly/4yPsiRQ

Now out in #JCO! 👇
Association Between Patient-Reported Outcomes and Health Care Resource Utilization: Toward Developing Patient-Centered Value Measures in Cancer Care.

Read the article. https://bit.ly/4hAysiE

Risk prediction in oral potentially malignant disorders remains one of the biggest unmet needs in oral oncology. This new review examines today's tools and where the field needs to go next.

Read the article. https://bit.ly/4hADn36

Now out in #JCO 👇
Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in Gastrointestinal Cancers: The Phase II ACT-GI Trial.

Read the article. https://bit.ly/4y2yjdH

Advance the science of oncology. As a JCO Journals reviewer, you can sharpen your own research skills while protecting the quality of cancer research.

Earn CME credits and FASCO™ points. Learn more and become a reviewer today: https://bit.ly/3VvklTa
#PeerReviewWeek

Turn your peer review time into career value. Reviewing for JCO Journals lets you earn CME credits and FASCO™ points and add verified experience to your CV.

Help safeguard accuracy, rigor, and scientific integrity in oncology: https://bit.ly/4xV6X9b